EMDR Institute, Inc.

GenVec receives NIAID’s Phase I SBIR grant to support RSV vaccine program

news-medical.net — “GenVec, Inc. announced today that it has received a Phase I Small Business Innovation and Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) to support the Company's Respiratory Syncytial Virus (RSV) vaccine program.” View full resource at news-medical.net

Most Recently Shared on May 4, 2012 at 6:13 am By:

GenVec receives NIAID’s Phase I SBIR grant to support RSV vaccine program: GenVec, Inc. announced today that it ... http://t.co/jltN39Bf

4 weeks ago...

IVD Technology Health Magazine

Asuragen Gains $6.8M Award on Next-Generation Sequencing | IVD Technology

ivdtechnology.com — “Asuragen Inc. received notice of a $6.8 million commercialization award to pursue next-generation sequencing (NGS) applications from the State of Texas through the Cancer Prevention and Research Institute of Texas (CPRIT). “NGS has generated excitement in life sciences and healthcare by facilitating the rapid and cost effective determination of large volumes of sequence information.” View full resource at ivdtechnology.com

Most Recently Shared on April 2, 2012 at 5:40 pm By:

Asuragen Gains $6.8M Award on Next-Generation Sequencing http://t.co/XFbsqpO9

Emergent receives NIAID grant to advance development of MVA85A TB vaccine

news-medical.net — “Emergent BioSolutions Inc. today announced that it has received a multi-year grant from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, to advance the development of MVA85A, a candidate vaccine against tuberculosis.” View full resource at news-medical.net

Most Recently Shared on March 23, 2012 at 10:56 am By:

News-Medical.Net Health News and Oncology

Oncology News: Emergent receives NIAID grant to advance development of MVA85A TB vaccine: Emergent BioSolutions ... http://t.co/UC1VKbHa

Diabetes, Type 2 OW Health

Profil Institute Continues to Publish New Findings in Metabolic Research - Yahoo! Finance

finance.yahoo.com — “From Yahoo! Finance: SAN DIEGO, March 21, 2012 /PRNewswire/ -- Profil ® Institute for Clinical Research, Inc., a company focused on early phase clinical trials for diabetes and obesity, announced today its continued focus ...” View full resource at finance.yahoo.com

Most Recently Shared on March 21, 2012 at 12:09 pm By:

Profil Institute Continues to Publish New Findings in Metabolic Research: SAN DIEGO, March 21, 2012 /PRNewswire/... http://t.co/KewME760

GeoVax enters into definitive agreements to sell Series A convertible preferred stock

news-medical.net — “GeoVax Labs, Inc., an Atlanta-based biopharmaceutical firm developing vaccines to prevent and fight Human Immunodeficiency Virus (HIV) infections, announced today that it has entered into definitive agreements with certain institutional investors, pursuant to which the Company has agreed to sell shares of its Series A convertible preferred stock at an aggregate purchase price of approximately $2.2 million and Series A warrants to purchase up to an aggregate of 2,933,333 shares of GeoVax common s” View full resource at news-medical.net

Most Recently Shared on March 21, 2012 at 7:59 am By:

HIV/AIDS News: GeoVax enters into definitive agreements to sell Series A convertible preferred stock: GeoVax Lab... http://t.co/uaGfb4wZ

Delcath receives first commercial order for CHEMOSAT system from IEO

news-medical.net — “Delcath Systems, Inc. announced today that it has received the first commercial order for the Company's Hepatic CHEMOSAT Delivery System from the European Institute of Oncology (Instituto Europeo di Oncologia – IEO) –a premier cancer treatment and research center in Europe.” View full resource at news-medical.net

Most Recently Shared on March 20, 2012 at 12:43 pm By:

Delcath receives first commercial order for CHEMOSAT system from IEO: Delcath Systems, Inc. announced today that... http://t.co/3HH73CRU

NIH awards Avaxia $1.5M Phase II SBIR grant to develop antibody therapeutic for IBD

news-medical.net — “Avaxia Biologics, Inc., a privately-held biotech company using its proprietary platform technology to develop orally-active antibody therapeutics for the treatment of gastrointestinal diseases, is proud to announce that it has received a second round of funding from the National Institutes of Health for its work in inflammatory bowel disease.” View full resource at news-medical.net

Most Recently Shared on March 19, 2012 at 8:17 pm By:

Diabetes News: NIH awards Avaxia $1.5M Phase II SBIR grant to develop antibody therapeutic for IBD: Avaxia Biolo... http://t.co/M9p8Mg9T

Adalimumab may decrease vascular inflammation in patients with psoriasis

news-medical.net — “A clinical study co-led by the Montreal Heart Institute and Innovaderm Research Inc., which was presented today at the annual meeting of the American Academy of Dermatology, shows that a new treatment for psoriasis could be associated with a significant decrease in vascular inflammation, a major risk factor of cardiovascular disease.” View full resource at news-medical.net

Most Recently Shared on March 17, 2012 at 7:38 am By:

Psoriasis OW OW Health

Adalimumab may decrease vascular inflammation in patients with psoriasis: A clinical study co-led by the Montrea... http://t.co/lYzmJMfP

QB3 renews and expands three-year agreement with Pfizer

news-medical.net — “The California Institute for Quantitative Biosciences (QB3) has renewed and expanded a three-year agreement with Pfizer Inc. to collaborate on research projects at the University of California with the potential to transform world-class science into better medicine.” View full resource at news-medical.net

Most Recently Shared on March 17, 2012 at 6:21 am By:

QB3 renews and expands three-year agreement with Pfizer: The California Institute for Quantitative Biosciences (... http://t.co/Bj51Svtt

Adalimumab may decrease vascular inflammation in patients with psoriasis

Most Recently Shared on March 17, 2012 at 5:19 am By:

Adalimumab may decrease vascular inflammation in patients with psoriasis: A clinical study co-led by the Montrea... http://t.co/23ZWMSBu

Treating psoriasis to prevent heart attacks and strokes

eurekalert.org — “A clinical study co-led by the Montreal Heart Institute and Innovaderm Research Inc., which was presented today at the annual meeting of the American Academy of Dermatology, shows that a new treatment for psoriasis could be associated with a significant decrease in vascular inflammation, a major risk factor of cardiovascular disease.” View full resource at eurekalert.org

Most Recently Shared on March 16, 2012 at 7:36 pm By:

Psoriasis OW OW Health

Treating psoriasis to prevent heart attacks and strokes: ( Montreal Heart Institute ) A clinical study co-led by... http://t.co/qJlnXlzC

QB3, Pfizer Expand Support for Translational Research

newswise.com — “The California Institute for Quantitative Biosciences (QB3) has renewed and expanded a three-year agreement with Pfizer Inc. to collaborate on research projects at the University of California with the potential to transform world-class science into better medicine.” View full resource at newswise.com

Most Recently Shared on March 16, 2012 at 6:42 pm By:

newswise Health Communicator and Health News

QB3, Pfizer Expand Support for Translational Research http://t.co/ESGwnLCX

PhysOrg Health News Health News

Treating psoriasis to prevent heart attacks and strokes

medicalxpress.com — “A clinical study co-led by the Montreal Heart Institute and Innovaderm Research Inc., which was presented today at the annual meeting of the American Academy of Dermatology, shows that a new treatment for psoriasis could be associated with a significant decrease in vascular inflammation, a major risk ...” View full resource at medicalxpress.com

Most Recently Shared on March 16, 2012 at 6:13 pm By:

Treating psoriasis to prevent heart attacks and strokes http://t.co/46VBkqzF

OrganizedWisdom OW Health

In wake of scandals, list highlights ethical firms - Yahoo! News

news.yahoo.com — “From Yahoo! News: (Reuters) - After a wave of scandals including wrongful foreclosures on home mortgages, worker suicides at a major Apple Inc supplier in China and the $1.7 billion accounting fraud at Japan's Olympus Corp, a New York think tank is calling out companies that take the high road. The Ethisphere Institute's annual World's Most Ethical companies list, released on Thursday, found that 145 companies in countries including United States, Great Britain, Japan, Portugal and India stood o” View full resource at news.yahoo.com

Most Recently Shared on March 15, 2012 at 1:45 pm By:

In wake of scandals, list highlights ethical firms: (Reuters) - After a wave of scandals including wrongful fore... http://t.co/FFc6eCvZ